Incyte Biosciences Distribution

Incyte is a global biopharmaceutical company headquartered in Wilmington, Delaware, specializing in the discovery and development of novel therapeutics for oncology, inflammation, and autoimmunity. The company is a pioneer in the field of Janus kinase (JAK) inhibition, having developed ruxolitinib, which is marketed as Jakafi for hematologic malignancies and Opzelura for dermatological conditions like vitiligo and atopic dermatitis. Beyond its core JAK franchise, Incyte has built a diverse portfolio including monoclonal antibodies, FGFR inhibitors, and IDH1 inhibitors. The company maintains a robust clinical pipeline with numerous programs in late-stage development for high-unmet-need indications such as hidradenitis suppurativa and various solid tumors. Through its international arm, Incyte Biosciences Distribution, the company manages the commercialization and supply chain of its approved therapies across global markets. Incyte continues to expand its footprint through strategic partnerships with major pharmaceutical firms like Novartis and Eli Lilly.